LOS ANGELES, Dec. 5 /PRNewswire/ -- Medical Tactile, Inc. (MTI) -- a medical device company specializing in tactile sensing technology -- today announced the start of commercial sales of its SureTouch Visual Mapping System for electronically documenting clinical breast exam results.
The system, which will be on display this week at the 28th San Antonio Breast Cancer Symposium (December 8-11), is cleared for commercial sale by the U.S. Food and Drug Administration as an adjunct device for performing and documenting clinical breast exams.
Based on the company’s proprietary tactile sensing technology, the SureTouch System improves the sensitivity, specificity and objectivity of manual breast palpation exams, which are the most accessible first line of defense against breast cancer for most women.
“We are very pleased to begin commercial sales of the first-of-its-kind SureTouch System,” said Steve Weiss, Medical Tactile’s CEO. “We have worked hard to develop an innovative, cost-effective technology that enables healthcare practitioners to improve early breast cancer diagnostics and save lives.”
The SureTouch system enhances and quantifies the operator’s sense of touch during manual palpation in breast cancer screening. To use the system, the healthcare practitioner simply palpates suspicious breast lesions with the hand-held tactile probe, which employs highly sensitive sensors clinically proven to map lesions as small as 5 mm. The portable SureTouch console creates an electronic record that provides a wealth of objective information to help recognize suspicious legions and make informed recommendations for follow-up radiological diagnostics such as mammography and ultrasound.
The SureTouch System is the company’s first commercially available tactile sensing device. Additional breast cancer detection products based on Medical Tactile’s proprietary technology are currently in development.
“Medical Tactile is committed to improving early breast cancer detection by providing affordable, easy-to-use tactile sensing technology,” Weiss added.
About MTI
Medical Tactile, Inc. (MTI) is an emerging medical device company focused on developing, manufacturing and marketing tactile sensing technology for the early detection of breast cancer. The Company’s first product is the SureTouch Visual Mapping System, which is designed to improve the sensitivity, specificity and objectivity of manual palpation in breast cancer screening. The system is cleared by the FDA for commercial sale in the U.S. More information about Medical Tactile, Inc. is available at www.medicaltactile.com.
Medical Tactile, Inc.
CONTACT: Erik Deutsch of ExcelPR Group, +1-323-851-2300, ext. 112,erikd@excelpr.com, for Medical Tactile, Inc.
Web site: http://www.medicaltactile.com/